Baxter Features Patient-Centered Innovation at the 2019 European Society of Intensive Care Medicine Congress
Baxter is broadening its innovative portfolio to meet the unique demands of critical care medicine Two Baxter-sponsored symposia will share clinical perspectives on extracorporeal organ support and personalized fluid management
Baxter International Inc., a leading global medical products company, will showcase its latest product innovations at the 2019 European Society of Intensive Care Medicine (ESICM) LIVES congress in Berlin from Sept. 28 – Oct. 2. The company will also host symposia to advance clinical knowledge in two emerging areas: extracorporeal (outside the body) organ support and the role of personalized fluid management for patients in the intensive care unit (ICU).
“We continue to advance innovation that purposefully addresses the unique complexities of treating critically ill patients,” said Reaz Rasul, general manager of Baxter’s Acute Therapies business. “There are unmet needs in this area of the hospital and we are committed to working alongside clinicians to improve outcomes, simplify care and help the ICU become more efficient.”
The following approved product innovations will be available for demonstrations in booth H:
- PrisMax System: Baxter’s next-generation system for continuous renal replacement therapy (CRRT) and organ support therapies is designed to improve the simplicity, accuracy and efficiency of therapy delivery.
- Oxiris 3-in-1 set: with an expanded indication to remove excessive levels of cytokines, endotoxin and other inflammatory mediators from a patient’s blood, Oxiris is the first blood purification set that can be used simultaneously in CRRT and sepsis management.
- Olimel N12: a recent addition to the company’s olive oil-based parenteral nutrition (PN) portfolio. Olimel N12 combines a high protein formulation with low glucose content, resulting in the lowest energy to protein ratio currently available in a standardized, triple-chamber bag.
- Q-NRG+: a metabolic monitoring device using indirect calorimetry, a technology which has been identified as the gold standard1 to accurately measure resting energy expenditure, or a patient’s calorie needs while at rest. Baxter and COSMED srl recently announced an agreement to commercialize Q-NRG+.
“Indirect calorimetry technology is the next step in nutrition therapy,” said Jorge Vasseur, general manager of Baxter’s Clinical Nutrition business. “The Q-NRG+ technology can determine accurate energy requirements that may help clinicians provide individualized nutrition interventions including parenteral nutrition (PN).”
Addressing Emerging Topics in Critical Care
To facilitate exchange of the latest clinical perspectives, Baxter will sponsor two congress symposia, open to attendees:
- “Extracorporeal organ support (ECOS) in the critically ill” – Monday, Sept. 30 from 12:30 – 14:00 CET
Four clinical experts will discuss the latest in ECOS, including the clinical rationale for extracorporeal CO2 removal, blood purification in septic patients and therapeutic plasma exchange in the ICU.
- “Road to Euvolemia: Personalized Fluid Management” – On Tuesday, Oct. 1 from 12:30 – 14:00 CET
A panel of international experts will discuss how a personalized approach to volume assessment and management can help achieve clinical goals.
